Literature DB >> 3609110

Duration of action of tiapamil in stable exercise induced angina.

M B Maltz, D W Davies, J L Caplin, A J Camm.   

Abstract

The duration of action of tiapamil was assessed in ten patients with stable exertional angina. Maximal symptom-limited treadmill exercise electrocardiography was performed before and at 1, 3, 6 and 9 h after therapy. Significant differences were only found at 1 h after tiapamil with increases in mean exercise duration (312 vs 399 s), the time to onset of angina (221 vs 310 s) and exercise work load (5.9 vs 7.3 METS). Tiapamil had no significant effect on the exercise heart rate but increased the resting heart rate by 6 beats/minute. The resting systolic blood pressure fell by 17 mmHg (p less than 0.01), and the diastolic blood pressure by 14 mmHg. Exercise systolic and diastolic blood pressures fell by 19 and 17 mmHg respectively. Side-effects were short-lived and attributable to vasodilatation. Tiapamil is effective for the relief of angina with minimal side-effects, but its duration of action is short. For effective chronic oral use, a sustained release preparation is required.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3609110     DOI: 10.1007/bf00543965

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.

Authors:  W G Austen; J E Edwards; R L Frye; G G Gensini; V L Gott; L S Griffith; D C McGoon; M L Murphy; B B Roe
Journal:  Circulation       Date:  1975-04       Impact factor: 29.690

Review 2.  Exercise stress testing in evaluation of patients with ischemic heart disease.

Authors:  R A Bruce; T R Hornsten
Journal:  Prog Cardiovasc Dis       Date:  1969-03       Impact factor: 8.194

3.  A new Ca++ antagonist, Ro 11-1781, and its metabolites. Synthesis and physicochemical properties.

Authors:  H Ramuz
Journal:  Arzneimittelforschung       Date:  1978

4.  Therapeutic implications of slow-channel blockade in cardiocirculatory disorders.

Authors:  G Ellrodt; C Y Chew; B N Singh
Journal:  Circulation       Date:  1980-10       Impact factor: 29.690

Review 5.  An overview of slow channel blocking drugs: pharmacological basis for therapeutic applications.

Authors:  B N Singh
Journal:  Cardiology       Date:  1982       Impact factor: 1.869

6.  Electrophysiology of tiapamil in concealed accessory pathways.

Authors:  R Gmeiner; C K Ng
Journal:  Cardiology       Date:  1982       Impact factor: 1.869

7.  Serial M-mode echocardiography in evaluation of the cardiovascular effects of tiapamil and their relationship to plasma levels in patients with coronary heart disease.

Authors:  K Lindvall; G Cocco; G Wendt; D Chu; P Heizmann
Journal:  Int J Cardiol       Date:  1981       Impact factor: 4.164

8.  Determination of tiapamil and of its two main metabolites in plasma and in urine by high-performance liquid chromatography.

Authors:  P Heizmann; G Wendt; R Von Alten; K Zinapold; C Buser
Journal:  J Chromatogr       Date:  1984-09-14

9.  Nifedipine therapy for Prinzmetal's angina.

Authors:  J E Muller; S J Gunther
Journal:  Circulation       Date:  1978-01       Impact factor: 29.690

10.  Verapamil in chronic stable angina. A controlled study with computerized multistage treadmill exercise.

Authors:  V B Subramanian; A Lahiri; R Paramasivan; E B Raftery
Journal:  Lancet       Date:  1980-04-19       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.